Header Logo

Connection

Jacob Rotmensch to Antibodies, Monoclonal

Back to Details
This is a "connection" page, showing publications Jacob Rotmensch has written about Antibodies, Monoclonal.
Jacob Rotmensch
Connection Strength
0.084
Antibodies, Monoclonal
  1. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2011 Jun 01; 29(16):2259-65.
    View in: PubMed
    Score: 0.084
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.